Navinci published a medRxiv preprint from Associate Professor Charlotte Stadler and collaborators using Navinci's isPLA technology to detect functional PD-1/PD-L1 immune checkpoint engagement in patient tumor tissue.

Navinci is a Swedish biotech company that specializes in developing innovative solutions for the study of protein interactions. With a focus and a strong legacy in the development of in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the field and has a broad portfolio of products that help researchers study protein interactions in depth. Our Naveni Proximity Ligation Technology is at the forefront of innovation within the field of spatial proteomics and allows for the detection and quantification of protein interactions and post-translational modifications in a manner that is both sensitive and specific. It provides researchers with a valuable tool for their studies and helps deepen the understanding of the interplay between proteins in their native environment. Our latest focus is on target-specific kits within immuno-oncology, which detect interactions such as PD1/PD-L1. These kits are designed to help researchers easily visualize the interactions between immune checkpoint proteins in immune and cancer cells and elucidate the role that interactions, rather than individual proteins, play in the development of cancer. By providing researchers with reliable and innovative tools for visualizing and interpreting protein interplay, Navinci pushes forward the understanding of cell biology and brings precision to spatial proteomics.

Founded 2004